NeuroDerm's Latest Clinical Data Accepted as Late Breaking News to the International Parkinson and Movement Disorder Society's 19th International Congress on June 14-18, 2015 in San Diego
June 09, 2015 07:00 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, June 9, 2015 (GLOBE NEWSWIRE) -- NeuroDerm (Nasdaq:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, announced the company...
NeuroDerm to Ring The Nasdaq Stock Market Opening Bell on June 3, 2015
June 02, 2015 10:00 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, June 2, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that...
NeuroDerm Announces First Quarter 2015 Financial Results and Provides Corporate Update
May 27, 2015 07:00 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, May 27, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm CEO to Present at Jefferies 2015 Healthcare Conference on June 1, 2015
May 26, 2015 07:00 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, May 26, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that...
NeuroDerm to Host First Quarter 2015 Financial Results Conference Call on May 27, 2015
May 20, 2015 12:58 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, May 20, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that...
NeuroDerm Announces Lifting of FDA Clinical Hold on ND0612, a Subcutaneously Delivered Levodopa/Carbidopa for the Treatment of Parkinson's Disease
May 08, 2015 07:00 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, May 8, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that...
NeuroDerm Files Annual Report on Form 20-F for the Year Ended December 31, 2014
April 29, 2015 07:30 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, April 29, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, announced today...
NeuroDerm Announces Fourth Quarter and 2014 Fiscal Year Financial Results and Provides a Corporate Update
April 02, 2015 07:00 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, April 2, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm to Announce Updated Topline Results of Phase II Study of Continuous, Subcutaneously-Delivered Levodopa/Carbidopa for the Treatment of Parkinson's Disease at the 67th Annual Meeting of the American Academy of Neurology
April 01, 2015 07:00 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, April 1, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, announced that...
NeuroDerm CEO to Present at Upcoming Investor Conferences
February 24, 2015 07:00 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, Feb. 24, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...